Form 4: Cellectar Biosciences Director Acquires Stock Options
Insider Transaction
Cellectar Biosciences Director Douglas J. Swirsky acquired 37,500 stock options with an exercise price of $2.70, vesting in full on July 7, 2027.
Summary
- Douglas J. Swirsky, a Director at Cellectar Biosciences, Inc., acquired 37,500 stock options.
- The stock options have an exercise price of $2.70 per share.
- These options are set to vest in full on July 7, 2027, contingent upon Mr. Swirsky's continued service.
- The transaction date was July 7, 2026, and the filing date was July 8, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard compensation practice for a director rather than a significant strategic move or financial performance indicator.
Positives
- Director acquisition of stock options can signal confidence in the company's future prospects.
- The acquisition of options at a specific exercise price indicates a potential future upside for the director.
Future Outlook
The stock options are exercisable at $2.70 and vest fully on July 7, 2027, suggesting a belief in potential future stock price appreciation.
Industry Context
StockSavvy.ai notes that insider option grants are common in the biotechnology sector as a means to incentivize and retain key personnel, aligning their interests with shareholders.
Stakeholder Impact
- Shareholders: The grant of options to a director is a standard compensation practice and may align director interests with shareholder value if the stock price increases.
- Employees: This transaction does not directly impact employees but is part of the company's overall compensation strategy.
- Management: The transaction is a routine part of executive and director compensation.
Next Steps
- Douglas J. Swirsky to continue service through July 7, 2027, for options to fully vest.
- Potential exercise of stock options if the stock price exceeds $2.70 before July 7, 2036.
Key Dates
| Date | Description |
|---|---|
| 07/07/2026 | Transaction date for the acquisition of stock options. |
| 07/07/2027 | Full vesting date for the acquired stock options, subject to continued service. |
| 07/07/2036 | Expiration date of the stock options. |
| 07/08/2026 | Date the SEC Form 4 was filed. |
Keywords
stock options, insider trading, Cellectar Biosciences, CLRB, director compensation, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.